2019
A Pathway Analysis of Hereditary Hemochromatosis-related Genes and Pancreatic Ductal Adenocarcinoma Risk (FS11-05-19)
Julián-Serrano S, Yu K, Yuan F, Wheeler W, Karimi P, Amundadottir L, Jacobs E, Kraft P, Li D, Petersen G, Risch H, Wolphin B, Klein A, Stolzenberg-Solomon R. A Pathway Analysis of Hereditary Hemochromatosis-related Genes and Pancreatic Ductal Adenocarcinoma Risk (FS11-05-19). Current Developments In Nutrition 2019, 3: nzz037.fs11-05-19. PMCID: PMC6573995, DOI: 10.1093/cdn/nzz037.fs11-05-19.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaHereditary hemochromatosis geneGenetic susceptibilityPDAC riskSingle nucleotide polymorphismsHereditary hemochromatosisHigh red meat intakeType 2 diabetes mellitusHemochromatosis geneRed meat intakePancreatic Cancer Case-Control ConsortiumIron-rich foodsType 2 diabetesPancreatic Cancer Cohort ConsortiumPancreatic ductal adenocarcinoma (PDAC) riskIntramural Research ProgramNational Cancer InstitutePathway analysisDiabetes mellitusAdenocarcinoma riskPrimary hemochromatosisRisk factorsChronic diseasesDuctal adenocarcinomaMeat intakeCurrent Approaches to Pancreatic Cancer Screening
Chhoda A, Lu L, Clerkin BM, Risch H, Farrell JJ. Current Approaches to Pancreatic Cancer Screening. American Journal Of Pathology 2019, 189: 22-35. PMID: 30558719, DOI: 10.1016/j.ajpath.2018.09.013.BooksConceptsPancreatic ductal adenocarcinomaHigh-risk individualsRisk factorsCancer syndromesHereditary breast-ovarian cancer syndromeBreast-ovarian cancer syndromeEarly resectable stagePancreatic cancer screeningScreening strategyFamilial atypical multipleCancer-related deathOvarian cancer syndromeCurrent screening strategiesLi-Fraumeni syndromePeutz-Jeghers syndromeGenetic risk factorsResectable stageCancer screeningPancreatic cancerChronic diseasesDuctal adenocarcinomaLynch syndromePrecursor lesionsLower incidenceFamilial history
2017
History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium
Minlikeeva AN, Consortium JL, Freudenheim KH, Eng RA, Cannioto G, Friel JB, Szender B, Segal K, Odunsi P, Mayor B, Diergaarde E, Zsiros LE, Kelemen M, Köbel H, Steed A, deFazio SJ, Group PA, Jordan MW, Fasching HA, Beckmann MA, Risch JA, Rossing J, Doherty MT, Chang-Claude T, Goodman R, Dörk F, Edwards RB, Modugno K, Ness M, Matsuo BY, Mizuno EL, Karlan SK, Goode E, Kjær JM, Høgdall KL, Schildkraut DW, Terry EV, Cramer LE, Bandera LA, Paddock LFAG, Kiemeney R, Massuger H, Sutphen A, Anton-Culver U, Ziogas SA, Menon SJ, Gayther A, Ramus CL, Gentry-Maharaj AH, Pearce J, Wu A, Kupryjanczyk PM, Jensen KB, Webb P, Moysich K. History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention 2017, 26: 1470-1473. PMID: 28864456, PMCID: PMC5649363, DOI: 10.1158/1055-9965.epi-17-0367.Peer-Reviewed Original ResearchConceptsProgression-free survivalHistory of endometriosisStage of diseaseOvarian cancer patientsOvarian cancer outcomeCancer outcomesCancer patientsCox proportional hazards regression modelProportional hazards regression modelsHazards regression modelsInvasive ovarian carcinomasOvarian cancer prognosisOvarian Cancer Association ConsortiumPooled HRsConcurrent comorbiditiesHistologic subtypeOvarian carcinomaChronic diseasesOvarian cancerWeight statusNeurologic diseaseCancer prognosisComorbiditiesTreatment efficacyNeurological diseases